Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Praluent
|
| gptkbp:aims_to |
improve patient outcomes
reduce cardiovascular events |
| gptkbp:analyzes |
cost-effectiveness
comorbid conditions quality of life measures biomarker data subgroup outcomes |
| gptkbp:collaborates_with |
research institutions
|
| gptkbp:conducted |
multiple countries
|
| gptkbp:contribution |
scientific knowledge
global health initiatives guidelines for cholesterol management clinical practice changes |
| gptkbp:examines |
long-term safety
|
| gptkbp:exhibited_at |
benefits of PCS K9 inhibitors
|
| gptkbp:focus |
lipid-lowering therapies
|
| https://www.w3.org/2000/01/rdf-schema#label |
ODYSSEY trials
|
| gptkbp:includes |
long-term follow-up
|
| gptkbp:influence |
clinical trial design
future research directions treatment guidelines |
| gptkbp:is_compared_to |
alirocumab to placebo
|
| gptkbp:is_evaluated_by |
therapeutic strategies
quality of care patient adherence patient-reported outcomes impact on healthcare systems dosing regimens effectiveness of alirocumab impact on cardiovascular mortality real-world effectiveness safety of alirocumab |
| gptkbp:is_involved_in |
interdisciplinary teams
patient engagement strategies multinational research teams patients with hypercholesterolemia |
| gptkbp:measures |
LDL cholesterol levels
|
| gptkbp:provides |
data for meta-analyses
evidence for reimbursement decisions |
| gptkbp:published_by |
medical journals
|
| gptkbp:receives_funding_from |
gptkb:Company
|
| gptkbp:recruitment |
high-risk cardiovascular patients
|
| gptkbp:reports_to |
findings at conferences
adverse events clinical outcomes safety profiles |
| gptkbp:result |
peer-reviewed journals
|
| gptkbp:sponsor |
gptkb:Sanofi
|
| gptkbp:student_enrollment |
thousands of participants
|
| gptkbp:supports |
regulatory submissions
patient education initiatives healthcare policy decisions clinical decision-making. |
| gptkbp:track |
treatment adherence
cholesterol levels over time |
| gptkbp:utilizes |
randomized controlled design
|